Clinical and Radiographic Evaluation of Biodentine Versus Formocresol
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03582319|
Recruitment Status : Completed
First Posted : July 11, 2018
Last Update Posted : July 11, 2018
|Condition or disease||Intervention/treatment||Phase|
|Pulp Disease, Dental||Other: Biodentine Other: Formocresol||Not Applicable|
Study design Randomized clinical trial, double blinded using split mouth technique. Study setting This study was carried out in Pediatric Dentistry Department-Faculty of Dentistry-Cairo University- Egypt.
Patients recruited for this study were selected according to the following criteria:
- Healthy children between 4 and 6 years of age with two matched bilateral deep carious primary mandibular first or second molars.
- No evident clinical symptoms of pulpal necrosis or pulp degeneration such as pain on percussion, spontaneous pain, history of swelling or presence of sinus tract.
- No pathologic or physiologic mobility.
- No radiographic evidence of internal and external resorption, pulp stone, and interradicular or periapical lesions (Preoperative radiograph).
- The remaining tooth structure would be restorable with a stainless steel crown.
- Bleeding time after amputation of the coronal pulp tissue was within normal limits (5 minutes).
Sample size calculation using sealedenvelop.com, (30) the online sample calculator, sample size was calculated assuming the null hypothesis that biodentine and formocresol have an average success rate of 95,99 % and 87.8 % respectively (26, 31,32,33). Thus planning a binary outcome non inferiority trial with a difference of 8.19 %, then 76 primary molars (38 per group) are required to be 90% sure that the upper limit of a one-sided 95% confidence interval will exclude a difference in favor of the standard group of more than 10% (34).
With an estimation of 10% annual dropout, sample size was set to 86 primary molars (43 per group) (35). Forty three children with the matching criteria of patient selection were included in this study.
Research Ethics Committee approval was obtained from Faculty of Dentistry Cairo University. Detailed treatment plan and procedures were explained to the parents and informed written consent s were obtained before practical work.
Randomization Using 4 times folded papers in which one of the tested materials was written (43 paper for each material) contained in a closed white envelops (43 envelop in each one folded paper of each tested materials were placed), the selected two matched bilateral deep carious primary mandibular molars were randomly allocated to one of the tested materials.
When guardians agreed for their child to participate in the trial, an envelope was drowned and patient personal data was written on it. At the time of treatment of the first tooth in each patient, one of the folded papers was taken from the envelope and the type of the dressing material was recorded. Trial participant and outcome assessors were blinded to the type of materials used in each tooth.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||43 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Randomized clinical trial, double blinded using split mouth technique.|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||Clinical and Radiographic Evaluation of Biodentine Versus Formocresol in Vital Pulpotomy of Primary Molars: (A Randomized Control Clinical Trial)|
|Actual Study Start Date :||February 12, 2017|
|Actual Primary Completion Date :||January 20, 2018|
|Actual Study Completion Date :||February 22, 2018|
Regenerative material for pulp therapy
Biodentine is mainly composed of tricalcium silicate, calcium carbonate and zirconium oxides while the liquid contains calcium chloride as the setting accelerator and water reducing agent
Active Comparator: Formocresol
Fixative agent for pulp therapy
Formocresol is a devitalizing and fixing agent which was introduced to dentistry since 1904 with full concentration of Buckley's formula (19% formaldehyde, 35 % cresol, and 15 % glycerin in distilled water). A five times diluted formula of Buckley's formocresol was used in this study.
Other Name: Tricresol formalin
- Assessing survival rate regarding absence of spontaneous pain over time. using a questionnaire. [ Time Frame: 3,6,9 and12 months. ]measurement of survival rate regarding absence of spontaneous pain and assessing the change over time ( binary outcome measured by direct questioning to the patient.
- Assessing absence of abscess, fistula or pathologic mobility over time using visual and clinical examination. [ Time Frame: 3, 6, 9 and 12 months. ]Absence of abscess, fistula or pathologic mobility ( binary outcome measured by visual and clinical examination).
- Absence of periapical or inter-radicular radiolucency (binary outcome detected by periapical x-ray ). [ Time Frame: 6 and 12 months. ]Absence of periapical or inter-radicular radiolucency (binary outcome detected by periapical x-ray ) with assessment of change over time.
- Absence of external or internal root resorption(binary outcome detected by periapical x-ray ) . [ Time Frame: 6 and 12 months ]Absence of external or internal root resorption(binary outcome detected by periapical x-ray ) with assessment of change over time.
- Absence of calcific metamorphosis in the radicular pulp canal (binary outcome detected by periapical x-ray ) . [ Time Frame: 6 and 12 months ]Absence of calcific metamorphosis in the radicular pulp canal (binary outcome detected by periapical x-ray ) with assessment of change over time.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03582319
|Cairo, Egypt, 11311|